Table 1

Baseline physical characteristics

Healthy controls (n=21)COPD (P) (n=27)COPD (S) (n=32)
Age (years)66.1 (1.0)66.9 (1.7)68.9 (1.7)
Gender (M:F)10:1114:1319:13
BMI (kg/m2)26.8 (0.6)25.5 (1.0)26.6 (0.8)
FFMI (kg/m2)17.5 (0.3)16.9 (0.4)17.6 (0.4)
Subjects with muscle wastage (n)076
Smoking pack years14.4 (5.1)* **48.1 (5.6)46.9 (7.9)
Physical activity score10.3 (1.2)* **6.1 (0.3)6.8 (1.1)
FEV1 (litres)2.5 (0.1)* **1.1 (0.0)1.12 (0.0)
FEV1 (% predicted)105.0 (4.7)* **45.8 (3.2)47.7 (3.3)
FEV1/FVC (%)71.8 (1.4)* **41.2 (2.1)39.42.4)
Thigh lean mass (g)4190 (189)3700 (191)3829 (153)
Isometric peak torque (Nm)135.8 (9.5)* **109.3 (9.8)105.9 (7.4)
Isokinetic peak torque (Nm)98.0 (7.9)**75.8 (6.9)79.9 (6.0)
Isokinetic peak work (J)373.8 (33.0)**284.5 (28.2)307.5 (25.2)
Cycle peak VO2 (ml/kg/min)22.8 (1.4)* **14.7 (0.9)14.4 (0.6)
Cycle peak workload (W)119.9 (8.7)* **51.1 (4.7)48.9 (3.8)
  • Subjects who provided a minimum of a baseline and 24 h muscle biopsy were included in the analysis (see online supplementary figure 1S). Figures refer to mean (SEM).

  • Details of the questionnaire used to measure physical activity score is given in the online supplementary materials and methods.

  • *p≤0.05; HC versus COPD (S); **p≤0.05; HC versus COPD (P).

  • BMI, body mass index; COPD (P), patients with COPD allocated placebo; COPD (S), patients with COPD allocated supplements; FFMI, fat-free mass index; HC, healthy control.